In 2004 Avastin was approved by the FDA for treatment of metastatic (cancer that has spread outside the local area) colon cancer. Heralded as the new chemo agent that would “change everything” for cancer patients. Immediately Roche began seeking other indications and usage for the drug to drive up their profits.